T1	food 29 45	grapefruit juice
T2	pharmacokinetics 71 85	concentrations
T3	food 183 199	grapefruit juice
T5	enzyme 231 237	CYP1A2
T6	drug 275 284	verapamil
T7	pharmacokinetics 285 302	biotransformation
T9	studyType 530 556	randomised crossover study
T10	drug 576 585	verapamil
T11	dosage 587 593	120 mg
T12	drug 595 602	Isoptin
T13	duration 626 632	7 days
T14	food 685 690	water
T15	drug 745 754	verapamil
T16	drug 759 783	norverapamil enantiomers
T17	interaction 1033 1042	increased
T18	pharmacokinetics 1122 1125	AUC
T20	pharmacokinetics 1247 1252	C(max
T21	value 1261 1270	1.63-fold
T22	interaction 1296 1304	increase
T23	drug 1387 1396	verapamil
T24	pharmacokinetics 1452 1455	AUC
T25	pharmacokinetics 1468 1473	C(max
T26	drug 1540 1549	verapamil
T27	drug 1554 1578	norverapamil enantiomers
T28	component 1622 1632	naringenin
T29	interaction 1733 1741	increase
T30	interaction 1818 1827	increased
T31	parameter 1836 1858	6-beta-hydroxycortisol
T32	drug 1923 1932	verapamil
T33	food 1963 1979	grapefruit juice
T34	drug 61 70	verapamil
T35	enzyme 140 157	cytochrome P(450)
T36	enzyme 158 166	(CYP)3A4
T37	interaction 170 179	inhibited
A1	valence T37 Diminution
T4	drug 385 394	verapamil
T38	population 429 508	Twenty-four young healthy volunteers of both sexes (12 smokers, 12 non-smokers)
#1	AnnotatorNotes T12	nom commercial
T8	frequency 618 621	bid
T39	frequency 710 715	daily
T40	drug 1043 1060	( R, S)-verapamil
T19	value 1148 1157	1.45-fold
T41	pharmacokinetics 1204 1229	peak plasma concentration
T42	drug 1406 1418	norverapamil
T43	parameter 893 905	PR intervals
T44	parameter 1667 1679	PR intervals
T45	pathology 1651 1679	Prolongation of PR intervals
#2	AnnotatorNotes T45	side effect
T46	enzyme 1904 1909	CYP3A
T47	value 1513 1535	0.61-fold to 0.85-fold
T48	drug 2021 2030	verapamil
T50	food 201 202	G
T51	food 680 681	G
T52	food 1017 1018	G
T53	food 1872 1873	G
T54	food 1794 1795	G
T55	food 1683 1684	G
T56	food 1594 1595	G
T60	pharmacokinetics 395 411	pharmacokinetics
T49	dosage 666 669	1 l
T57	pharmacokinetics 727 741	concentrations
T59	pharmacokinetics 850 876	pharmacokinetic parameters
T61	pharmacokinetics 1065 1104	area under the concentration-time curve
T62	pharmacokinetics 1308 1322	concentrations
T63	drug 1335 1361	( R)- and ( S)-enantiomers
T64	pharmacokinetics 1633 1649	pharmacokinetics
T65	parameter 1828 1835	urinary
T66	interaction 1883 1892	induction
T67	value 1748 1754	350 ms
R1	metabolism_decrease Arg1:T52 Arg2:T40	
R2	enzyme_inhibition Arg1:T52 Arg2:T40	
